Role of Denosumab and Zoledronic Acid in Geriatric Hip Fractures – A Comparative Analysis

Author:

Madhuchandra P.1,Nandeesh S.1,Raju K. P.1

Affiliation:

1. Department of Orthopaedics, BGS Global Institute of Medical Sciences, Bengaluru, Karnataka, India

Abstract

Abstract Background: Osteoporotic hip fractures are on the raise in the world. Denosumab and zoledronic acid are among the commonly used current anti-osteoporotic medications to reduce hip fractures. The purpose of the present study was to compare the effectiveness and adverse events of denosumab and zoledronic acid in geriatric patients after a hip fracture. Materials and Methods: A prospective observational study was conducted between February 2020 and May 2021, and a total of 104 patients were included in the study. Fifty-three patients were given subcutaneous (SC) denosumab once in 6 months, and 51 patients were given intravenous (IV) zoledronic acid. The percentage changes in the Bone Mineral Density (BMD) values from the baseline values were compared between both the groups at 0, 12, and 24 months. Results: The percentage increase in lumbar-bone mineral density (L-BMD) was higher significantly in the denosumab group when compared to the zoledronic acid group at 12 months (6.8 ± 0.9 vs. 4.5 ± 0.7; P < 0.01) and 24 months (9.2 ± 0.9 vs. 7.1 ± 0.8; P < 0.001). There was a significant percentage change in the hip-bone mineral density (BMD) in both the groups; however, a higher mean percentage change was noted in the denosumab group when compared to the zoledronic acid group at 12 months and 24 months (P < 0.04 and P < 0.001). Conclusion: We conclude that SC-given denosumab has got a better efficacy on comparison with the IV-given zoledronic acid. Randomized control trials with a large sample size and longer follow-up are required to come to conclusion regarding patient safety, compliance, and persistence.

Publisher

Medknow

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3